Free Trial

Nkarta (NKTX) Competitors

Nkarta logo
$2.28 -0.21 (-8.23%)
As of 11:28 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NKTX vs. CMPS, NAGE, SIGA, CMPX, OPT, SVRA, KALV, BCYC, CTMX, and RGNX

Should you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include COMPASS Pathways (CMPS), Niagen Bioscience (NAGE), Siga Technologies (SIGA), Compass Therapeutics (CMPX), Opthea (OPT), Savara (SVRA), KalVista Pharmaceuticals (KALV), Bicycle Therapeutics (BCYC), CytomX Therapeutics (CTMX), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.

Nkarta vs. Its Competitors

Nkarta (NASDAQ:NKTX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 8.4% of Nkarta shares are owned by insiders. Comparatively, 3.9% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

COMPASS Pathways is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/A-$108.79M-$1.48-1.54
COMPASS PathwaysN/AN/A-$155.12M-$1.84-3.42

Nkarta presently has a consensus target price of $13.50, suggesting a potential upside of 490.81%. COMPASS Pathways has a consensus target price of $16.00, suggesting a potential upside of 154.57%. Given Nkarta's higher possible upside, analysts plainly believe Nkarta is more favorable than COMPASS Pathways.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nkarta
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
COMPASS Pathways
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

Nkarta's return on equity of -27.74% beat COMPASS Pathways' return on equity.

Company Net Margins Return on Equity Return on Assets
NkartaN/A -27.74% -22.38%
COMPASS Pathways N/A -87.89%-57.77%

In the previous week, COMPASS Pathways had 8 more articles in the media than Nkarta. MarketBeat recorded 10 mentions for COMPASS Pathways and 2 mentions for Nkarta. Nkarta's average media sentiment score of 0.77 beat COMPASS Pathways' score of 0.64 indicating that Nkarta is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nkarta
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
COMPASS Pathways
3 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Nkarta has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500.

Summary

Nkarta beats COMPASS Pathways on 9 of the 13 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKTX vs. The Competition

MetricNkartaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$163.01M$3.40B$6.08B$10.48B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio-1.5522.6784.6926.97
Price / SalesN/A477.88596.04130.44
Price / CashN/A46.9737.8662.13
Price / Book0.4010.3912.286.56
Net Income-$108.79M-$52.47M$3.32B$276.78M
7 Day Performance5.79%1.53%1.30%0.80%
1 Month Performance19.63%13.74%8.49%4.02%
1 Year Performance-42.88%12.10%72.74%34.82%

Nkarta Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKTX
Nkarta
2.4406 of 5 stars
$2.29
-8.2%
$13.50
+490.8%
-42.6%$163.01MN/A-1.55140Gap Down
CMPS
COMPASS Pathways
2.9701 of 5 stars
$6.29
+1.1%
$16.00
+154.4%
+2.1%$596.76MN/A-3.42120News Coverage
Gap Down
NAGE
Niagen Bioscience
2.6472 of 5 stars
$7.46
-0.3%
$13.42
+79.9%
N/A$596.55M$99.60M35.53120
SIGA
Siga Technologies
1.9368 of 5 stars
$8.26
+0.5%
N/A+22.8%$588.60M$138.72M7.3140Options Volume
CMPX
Compass Therapeutics
2.8092 of 5 stars
$4.28
+0.9%
$13.10
+206.1%
+128.3%$586.32M$850K-9.5120
OPT
Opthea
0.3654 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
-32.9%$583.10M$30K0.008News Coverage
Analyst Forecast
Gap Up
High Trading Volume
SVRA
Savara
3.0807 of 5 stars
$3.41
+1.2%
$7.50
+119.9%
-4.3%$582.46MN/A-6.8220Trending News
Analyst Upgrade
Analyst Revision
KALV
KalVista Pharmaceuticals
3.6643 of 5 stars
$11.32
-1.6%
$26.43
+133.5%
-10.5%$581.02MN/A-2.87100
BCYC
Bicycle Therapeutics
3.5543 of 5 stars
$8.12
-2.4%
$22.22
+173.7%
-68.6%$576.63M$35.28M-2.31240News Coverage
Analyst Forecast
CTMX
CytomX Therapeutics
4.3323 of 5 stars
$3.40
+1.2%
$5.42
+59.3%
+178.0%$554.11M$138.10M6.07170
RGNX
REGENXBIO
4.4232 of 5 stars
$11.34
+3.8%
$28.38
+150.2%
+14.8%$551.61M$83.33M-3.30370Gap Down

Related Companies and Tools


This page (NASDAQ:NKTX) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners